Mark Sulkowski

47.6k total citations · 9 hit papers
411 papers, 26.9k citations indexed

About

Mark Sulkowski is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Mark Sulkowski has authored 411 papers receiving a total of 26.9k indexed citations (citations by other indexed papers that have themselves been cited), including 360 papers in Hepatology, 274 papers in Epidemiology and 117 papers in Infectious Diseases. Recurrent topics in Mark Sulkowski's work include Hepatitis C virus research (357 papers), Liver Disease Diagnosis and Treatment (197 papers) and Hepatitis B Virus Studies (167 papers). Mark Sulkowski is often cited by papers focused on Hepatitis C virus research (357 papers), Liver Disease Diagnosis and Treatment (197 papers) and Hepatitis B Virus Studies (167 papers). Mark Sulkowski collaborates with scholars based in United States, Germany and France. Mark Sulkowski's co-authors include David L. Thomas, John G. McHutchison, Andrew J. Muir, Richard K. Sterling, Ira M. Jacobson, Mark Nelson, Francesca J. Torriani, Ricard Solà, Doug Dieterich and Eduardo Lissen and has published in prestigious journals such as Nature, New England Journal of Medicine and JAMA.

In The Last Decade

Mark Sulkowski

395 papers receiving 26.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

2006 3.5k citations Richard K. Sterling, Mark Sulkowski et al. profile →
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

2009 2.6k citations Mark Sulkowski et al. profile →
Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2011 1.9k citations Fred Poordad, Bruce R. Bacon et al. profile →
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 889 citations Eric Lawitz, Mitchell L. Shiffman et al. profile →
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 803 citations Gregory T. Everson, Stuart C. Gordon et al. profile →
Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection

2000 745 citations Mark Sulkowski profile →
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

2011 566 citations David R. Nelson, Mark Sulkowski et al. profile →
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection

2017 504 citations Oluwaseun Falade‐Nwulia, David R. Nelson et al. Annals of Internal Medicine profile →
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 395 citations Ira M. Jacobson, Fred Poordad et al. profile →

Peers

Countries citing papers authored by Mark Sulkowski

Since Specialization

Citations

This map shows the geographic impact of Mark Sulkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sulkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sulkowski more than expected).

Fields of papers citing papers by Mark Sulkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sulkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sulkowski. The network helps show where Mark Sulkowski may publish in the future.

Co-authorship network of co-authors of Mark Sulkowski

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Sulkowski. A scholar is included among the top collaborators of Mark Sulkowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Sulkowski. Mark Sulkowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment 2025 ·Journal of Clinical Investigation ·(unknown), (unknown), (unknown), Mark Anderson, Gavin Cloherty, Hyon S. Hwang, (unknown), (unknown), (unknown), Mark Sulkowski, Richard K. Sterling, Yang Zhang, Ruy M. Ribeiro, David L. Thomas, Chloe L. Thio, Ashwin Balagopal	1
2	Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life 2025 ·Quality of Life Research ·Thiago S. Torres, (unknown), Laura Smeaton, (unknown), Dimas Alexandre Kliemann, Anchalee Avihingsanon, Cissy Kityo, (unknown), Marije Van Schalkwyk, Benjamin P. Linas, Estêvão Portela Nunes, Gregory K. Robbins, David Wyles, Susanna Naggie, Mark Sulkowski, Sandra Wagner Cardoso, Sunil S. Solomon	0
3	High-dimensional droplet digital PCR of multiple hepatitis B splice variants in serum, liver, and tissue culture 2025 ·Journal of Virological Methods ·(unknown), Chenkai Jiang, (unknown), Nicole Skinner, Mark Sulkowski, Ashwin Balagopal, Chloe L. Thio	0
4	Cardiometabolic health in people with HIV: expert consensus review 2024 ·Journal of Antimicrobial Chemotherapy ·Rachel L. Batterham, Roger Bedimo, Ricardo Sobhie Diaz, Giovanni Guaraldi, Janet Lo, Estebán Martínez, Grace A. McComsey, Ana Milinkovic, (unknown), Sebastian Noé, Donal O’Shea, Roger Paredes, Jonathan Schapiro, Mark Sulkowski, François Venter, Laura Waters, (unknown), Benjamin Young	7
5	Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease 2024 ·The American Journal of Gastroenterology ·Richard K. Sterling, Eduardo Vilar‐Gómez, Laura Wilson, Rohit Loomba, Samer Gawrieh, Jennifer C. Price, Susanna Naggie, Jordan E. Lake, Sonya L. Heath, James Tonascia, Mark Sulkowski, Naga Chalasani, (unknown)	2
6	Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus 2023 ·The Journal of Infectious Diseases ·Jaiprasath Sachithanandham, Ashwin Balagopal, (unknown), Jeffrey Quinn, (unknown), Kathleen Ward, Ruy M. Ribeiro, Mark Sulkowski	1
7	Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations 2023 ·Clinical Infectious Diseases ·Jordan J. Feld, Julie Bruneau, Gregory J. Dore, Marc G. Ghany, Bettina E. Hansen, Mark Sulkowski, David L. Thomas	6
8	Implementing a peer-supported, integrated strategy for substance use disorder care in an outpatient infectious disease clinic is associated with improved patient outcomes 2023 ·International Journal of Drug Policy ·Oluwaseun Falade‐Nwulia, (unknown), Sharon M. Kelly, Ju Nyeong Park, Sheree Schwartz, (unknown), (unknown), Joyce Jones, Jeanne Keruly, Nishant R. Shah, Catherine R. Lesko, Gregory M. Lucas, Mark Sulkowski	5
9	A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection 2021 ·Clinical Gastroenterology and Hepatology ·Raymond Chung, Wendy C. King, Marc G. Ghany, Mauricio Lisker‐Melman, Amanda S. Hinerman, Mandana Khalili, Mark Sulkowski, Mamta K. Jain, Eun-Young Choi, Michael A. Nalesnik, Atul K. Bhan, Gavin Cloherty, David Wong, Richard K. Sterling	3
10	Network‐based recruitment of people who inject drugs for hepatitis C testing and linkage to care 2020 ·Journal of Viral Hepatitis ·Oluwaseun Falade‐Nwulia, Kathleen Ward, (unknown), Shruti H. Mehta, Stephanie Pitts, (unknown), Geetanjali Chander, David L. Thomas, Mark Sulkowski, Carl A. Latkin	21
11	Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland 2020 ·Journal of Viral Hepatitis ·Risha Irvin, (unknown), Mary B. Kleinman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lucy Wilson, Alexander J. Millman, Noele P. Nelson, Lauren Canary, Sherilyn Brinkley, Juhi Moon, Oluwaseun Falade‐Nwulia, Mark Sulkowski, David L. Thomas, Michael T. Melia	7
12	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy 2019 ·Gastroenterology ·Anna S. Lok, Mark Sulkowski, Jens Kort, Ira Willner, K. Rajender Reddy, Mitchell L. Shiffman, Mohamed A. Hassan, Brian L. Pearlman, Federico Hinestrosa, Ira M. Jacobson, Giuseppe Morelli, Joy Peter, Monika Vainorius, (unknown), Michael Fried, Gary P. Wang, Wenjing Lü, Lois Larsen, David R. Nelson	34
13	Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV 2019 ·The Lancet HIV ·Robert C. Bollinger, Chloe L. Thio, Mark Sulkowski, Jane McKenzie‐White, David L. Thomas, Charles Flexner	30
14	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients 2018 ·Annals of Internal Medicine ·Christine M. Durand, Mary G. Bowring, Diane Brown, Michael A. Chattergoon, Guido Massaccesi, (unknown), Russell Wesson, Ashraf Reyad, Fizza Naqvi, Darin Ostrander, Jeremy Sugarman, Dorry L. Segev, Mark Sulkowski, Niraj M. Desai	2
15	Patient‐reported outcomes in patients co‐infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL‐5 study 2017 ·Liver International ·Zobair M. Younossi, Maria Stepanova, Mark Sulkowski, David Wyles, Shyam Kottilil, Sharon Hunt	29
16	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study 2016 ·Gut ·Tania M. Welzel, David R. Nelson, Giuseppe Morelli, Adrian M. Di Bisceglie, K. Rajender Reddy, Alexander Kuo, Joseph K. Lim, Jama M. Darling, Paul J. Pockros, Joseph Galati, Lynn M. Frazier, Saleh A. Alqahtani, Mark Sulkowski, Monika Vainorius, Lucy Akushevich, Michael Fried, Stefan Zeuzem	61
17	Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection 2014 ·Alimentary Pharmacology & Therapeutics ·Sammy Saab, Stuart C. Gordon, (unknown), Mark Sulkowski, Aijaz Ahmed, Zobair M. Younossi	52
18	Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin 2013 ·Alimentary Pharmacology & Therapeutics ·Stuart C. Gordon, Eric M. Yoshida, Eric Lawitz, Bruce R. Bacon, Mark Sulkowski, Mitchell Davis, Fred Poordad, J.‐P. Bronowicki, Rafael Esteban, Vilma Sniukiene, Margaret Burroughs, Weiping Deng, Frank J. Dutko, Clifford A. Brass, Janice K. Albrecht, K. Rajender Reddy	17
19	Cervical injection drug use: a pain in the neck. 2010 ·PubMed ·James H. Tabibian, Mark Sulkowski	0
20	Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. 2006 ·PubMed ·Vijayan Balan, David R. Nelson, Mark Sulkowski, Gregory T. Everson, Louis R. Lambiase, (unknown), Rolland C. Dickson, Andy Garcia, Paul A. Moore, (unknown), G. Mani Subramanian	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact